Patents by Inventor Stefan Wildt

Stefan Wildt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050208617
    Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII activity, which produce bisected N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.
    Type: Application
    Filed: October 7, 2003
    Publication date: September 22, 2005
    Inventors: Piotr Bobrowicz, Stephen Hamilton, Tilman Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Nett, Robert Davidson
  • Publication number: 20050170452
    Abstract: The present invention relates to host cells having modified lipid-linked oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells have a GlcNAcMan3GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g., glycosyl-transferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.
    Type: Application
    Filed: December 24, 2002
    Publication date: August 4, 2005
    Inventors: Stefan Wildt, Robert Miele, Juergen Nett, Robert Davidson
  • Publication number: 20040018590
    Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.
    Type: Application
    Filed: February 20, 2003
    Publication date: January 29, 2004
    Inventors: Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson
  • Publication number: 20030027175
    Abstract: The present invention relates to a methodology for discovering genes responsible for a particular phenotype. The subject method can be used with a variety of cell types, including eukaryotic and prokaryotic cells, and for determining the role of genes and gene programs in the various growth states of those cells and responses to drugs or other environmental cues.
    Type: Application
    Filed: February 13, 2002
    Publication date: February 6, 2003
    Inventors: Gregory Stephanopoulos, Ryan T. Gill, Stefan Wildt